Showing 1781-1790 of 7092 results for "".
Addressing Itch in Prurigo Nodularis Clinical Trials
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37170/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, addresses how future prurigo nodularis trials could better address the heterogeneity in disease burden and patient-reported outcomes.Food Allergies and Atopic Dermatitis in the Pediatric Population
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/food-allergies-and-atopic-dermatitis-in-the-pediatric-population/37175/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses potential links between food allergies and pediatric atopic dermatitis, and how to address them.Ensuring Equity for Your Patients
https://practicaldermatology.com/series/the-practical-dermatology-podcast/ensuring-equity-for-your-patients/54335/Jeanine Downie, MD, FAAD, and an expert panel discuss implicit bias and discrimination against various marginalized populations and how to be proactive in avoiding these problems in your practice. Joining Dr. Downie are Drs. Mona Gohara, Anthony Rossi, Jacob Beer, and Jane Yoo. This discussion is baDermwire TV: 2025 in Review
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-2025-in-review/54093/Dermwire TV takes a look back at the most popular stories from the Practical Dermatology news and multimedia ecosystem.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaDermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.Regenerative Treatments in Dermatology
https://practicaldermatology.com/series/c-suite-chats/regenerative-treatments-in-dermatology/37707/John Aylworth, PhD, CEO and founder of Xytogen Biotech, talks about the growing demand for regenerative treatments in dermatology and new options for the treatment room.What’s New in Psoriasis
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39743/Chris Bunick, MD, FAAD, talks about new therapeutic directions, real‑world data, and challenges in psoriasis management. This video was recorded at the Science of Skin Summit in Austin, TX.Growing into the Role of a KOL
https://practicaldermatology.com/programs/practical-dermatology/tbd/39738/Michael H. Gold, MD, founder/medical director of Gold Skin Care Center, shares his path and strategies becoming a key opinion leader in dermatology. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to priv